Revolutionary Protein Degraders Integrated into Antibody-Drug Conjugates: Carolyn Bertozzi and Versant Launch New Biotech with $94 Million Funding
Carolyn Bertozzi, Versant Ventures, Firefly Bio, Protein degraders, Antibody-drug conjugates (ADCs), Degrader-Antibody Conjugates (DACs), $94 million funding
Eicos Sciences’ Aurlumyn: First FDA-Approved Treatment for Severe Frostbite Reduces Amputation Risk
Aurlumyn, Eicos, Amputation, Sciences’, iloprost, severe frostbite
Pharma Executives of BMS, J&J, and Merck Confronted in Senate Hearing on Sky-High Drug Prices
United States, Prices, CEOs, Country, Johnson and Johnson, R&D, Merck
Neurona Raises $120M Bolstered by Promising Early-Stage Data for Epilepsy Cell Therapy NRTX-1001
Epilepsy, NRTX-1001, Seizures, Neurona, Cell Therapy
BioNTech Boosts CAR-T Manufacturing Prowess with Autolus Investment and mRNA Synergy
BioNTech, CAR-T, Manufacture, Investments, Autolus
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024
Kyowa Kirin Partners with BridgeBio for Potential Achondroplasia Drug, Pays $100M in Pivotal Collaboration
Achondroplasia, infigratinib, BridgeBio, Kyowa, Kirin, Collaboration